Skip to Content

Cardinal Health Inc CAH Stock Quote

| Rating as of

Morningstar‘s Stock Analysis CAH

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Cardinal Health Shows Resilience Amid Cost Inflation; Raising FVE to $67

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We are raising our fair value estimate on narrow-moat Cardinal Health to $67 from $52 per share after diving deeper into our assumptions and coming away with a more favorable outlook for the company overall. We have also factored in its strong fourth-quarter performance. Results in the firm’s core distribution business were consistent with rebounding prescription drug volume and primary-care patient visits. Meanwhile, the impact of cost inflation was less severe than anticipated, which we believe signals a more positive start to 2023. Management’s guidance for next year includes low-double-digit revenue growth and low-single-digit profit growth in the distribution segment. We expect supply headwinds will be strongest in the first half of the year.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CAH

Company Profile CAH

Business Description

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Contact
7000 Cardinal Place
Dublin, OH, 43017
T +1 614 757-5000
Industry Medical Distribution
Most Recent Earnings Jun 30, 2022
Fiscal Year End Jun 30, 2023
Employees 46,500

Related News CAH